Compositions and methods for treating metabolic disorders
A method of treating a metabolic disorder includes identifying a subject having a metabolic disorder and administering to the subject a therapeutically effective amount of GM201, wherein the therapeutically effective amount is between 0.1 mg/kg and 500 mg/kg with respect to a body weight of the subject.
1 . A method of treating a metabolic disorder, the method comprising:
identifying a subject having a metabolic disorder; and
administering to the subject a therapeutically effective amount of GM201 to treat the metabolic disorder, wherein the therapeutically effective amount is between 0.1 mg/kg and 500 mg/kg with respect to a body weight of the subject.
2 . The method of claim 1 , wherein the therapeutically effective amount of GM201 is between 5 mg/kg and 50 mg/kg with respect to the body weight of the subject.
3 . The method of claim 1 , wherein the therapeutically effective amount of GM201 is between 10 mg/kg and 30 mg/kg with respect to the body weight of the subject.
4 . The method of claim 1 , wherein GM201 comprises a molecular weight of approximately 84-88 kDa.
5 . The method of claim 1 , wherein GM201 comprises 120-132 copies of Thomsen-Friedenreich disaccharide.
6 . The method of claim 1 , wherein the therapeutically effective amount of GM201 is administered via one or more means selected from a group consisting of an edible formulation, a pharmaceutical formulation, an oral administration, a sublingual administration, an intranasal formulation, an intraocular formulation, a rectal administration, a transdermal administration, a mucosal administration, a pulmonary administration, a topical administration, and a parenteral administration including an intradermal administration, a subcutaneous (SC) administration, an intramuscular (IM) administration, an intravenous (IV) administration, an intraperitoneal (IP) administration, an intraarterial administration, an intramedullary administration, an intracardiac administration, an intraarticular administration, an intrasynovial administration, an intracranial administration, an intraspinal administration, and an intrathecal administration.
7 . The method of claim 1 , wherein the metabolic disorder comprises type 2 diabetes.
8 . The method of claim 1 , wherein the metabolic disorder comprises fibrosis.
9 . The method of claim 8 , wherein the fibrosis comprises liver fibrosis.
10 . The method of claim 8 , wherein the fibrosis comprises pulmonary fibrosis.
11 . The method of claim 10 , wherein the pulmonary fibrosis comprises idiopathic pulmonary fibrosis (IPF).
12 . The method of claim 1 , wherein the metabolic disorder comprises ulcerative colitis (UC).
13 . The method of claim 1 , further comprising administering to the subject a glucagon-like peptide 1 (GLP-1) receptor agonist.
14 . The method of claim 13 , wherein the GLP-1 receptor agonist includes one or more members selected from a group consisting of dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide.
15 . A method of treating a subject with a metabolic disorder, the method comprising:
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising GM201, wherein therapeutically effective amount includes between 0.1 mg/kg and 500 mg/kg of GM201 with respect to a body weight of the subject.
16 . The method of claim 15 , wherein the pharmaceutical composition is in a form of a solution comprising GM201.
17 . The method of claim 15 , wherein the pharmaceutical composition further comprises an excipient.
18 . The method of claim 15 , wherein the pharmaceutical composition is self-administered by subcutaneous injection using a prefilled cartridge comprising the pharmaceutical composition.
19 . The method of claim 15 , wherein the pharmaceutical composition further comprises a glucagon-like peptide 1 (GLP-1) receptor agonist.
20 . The method of claim 15 , further comprising expressing GM201 using Chinese hamster ovary (CHO) cells.